Mov Disord Vol 33, Suppl 2 Archives - Page 158 of 177 - MDS Abstracts

2018 International Congress
A53T mutant human α-synuclein BAC transgenic mice as a model for Parkinson’s disease
T. Taguchi, I. Masashi, M. Uemura, Y. Hatanaka, N. Uemura, H. Yamakado, R. Takahashi (Kyoto, Japan)
Objective: The aim of this study is to create mouse models reproducing the course of PD pathology and symptoms. Background: Parkinson's disease (PD) is a…
2018 International Congress
Evidence based management of Normal Pressure Hydrocephalus: Lessons and future directions
A. Mahajan, M. Macki, M. Kaur, M. Novikova, R. Shatz, J. Schwalb (Detroit, MI, USA)
Objective: To present the methodology and management tree of patients referred to the Henry Ford NPH conference for an evaluation from 2003 to 2017. Background:…
2018 International Congress
Cerebellar signs in progressive supranuclear palsy
D. Crosiers, A. Sieben, J. Baets, J.J. Martin, P. Cras (Edegem, Belgium)
Objective: To present a patient with cerebellar ataxia and a pathologically confirmed diagnosis of PSP. Background: Progressive supranuclear palsy (PSP) is an atypical form of…
2018 International Congress
MSA Preliminary Panamerican Report
M. Cesarini, E. Gatto, J. Etcheverry, G. Da Prat, N. Gonzalez Rojas, H. Teive, M. Rodriguez, J. Ziliani, M. Miranda, P. Chana, F. Cardoso, A. Cardozo, C. Uribe Roca, I. Amorin, L. Abaroa, c. Cosentino, Y. Nuñez, A. Lescano, E. Dieguez, A. Alleva, I. Litvan, G. Wenning (La Plata, Argentina)
Objective: To report the results of the PAN American MSA (PANMSA) database Background: Multiple system atrophy (MSA) is a rare neurodegenerative disease and coordinated efforts…
2018 International Congress
Serum insulin-like growth factor-1 levels in parkinsonism or dementia disorders
K. Suzuki, S. Suzuki, Y. Ishii, T. Matsubara, H. Fujita, Y. Watanabe, M. Okamura, T. Kadowaki, H. Sakuramoto, K. Hirata (Tochigi, Japan)
Objective: To investigate serum insulin growth factor-1 (IGF-1) levels in neurodegenerative disease and to correlate clinical parameters. Background: IGF-1 is highly expressed in the central…
2018 International Congress
Rapamycin for treating MSA: A preclinical proof of concept study
M. Lopez-Cuina, P. Guerin, E. Bezard, W. Meissner, P-O. Fernagut (Bordeaux, France)
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…
2018 International Congress
Assessment of CSF biomarkers clinical value in Progressive Supranuclear Palsy
T. Schirinzi, G. Sancesario, G. Di Lazzaro, N. Mercuri, S. Bernardini, A. Lang, A. Pisani (Rome, Italy)
Objective: To evaluate diagnostic and prognostic usefulness of a panel of CSF biomarkers in PSP patients presenting with Richardson’s Syndrome (RS). Background: PSP is a…
2018 International Congress
Finger Tapping Profile in “On State” PD Patients
JP. Romero, I. Serrano, D. Del Castillo, A. Arroyo, V. Cortés, J. Andreo, J. Periañez, M. Rios (Madrid, Spain)
Objective: We intent to explore the tapping profile in PD patients in "ON state" compared to controls in repetitive trials to clarify if motor control…
2018 International Congress
Physical activity in people with Parkinson’s disease: A qualitative study
J. McGinley, M. Danoudis, B. BIlney, M. Morris, R. Higgins (Parkville, Australia)
Objective: This study aimed to investigate how Australians with Parkinson’s disease (PD) perceive participation in physical activity, and to identify barriers and enablers. Background: Exercise…
2018 International Congress
Annual Clinical Evaluation in Out Patient Clinic May Improve Quality of Life in Patients with Parkinson’s Disease
M. Tomiyama, T. Ueno (Aomori, Japan)
Objective: The aim of this study was to examine whether the annual clinical evaluation system improves QOL in Parkinson’s disease (PD) patients. Background: We perform…